ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 242 filers reported holding ACCELERON PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $90,964,000 | +419.9% | 528,554 | +279.1% | 0.03% | +433.3% |
| Q2 2021 | $17,497,000 | +11.8% | 139,425 | +20.9% | 0.01% | -14.3% |
| Q1 2021 | $15,645,000 | +348.7% | 115,366 | +323.3% | 0.01% | +600.0% |
| Q4 2020 | $3,487,000 | -52.1% | 27,256 | -57.9% | 0.00% | -80.0% |
| Q3 2020 | $7,277,000 | -75.5% | 64,673 | -79.3% | 0.01% | -78.3% |
| Q2 2020 | $29,738,000 | +302.1% | 312,143 | +279.4% | 0.02% | +228.6% |
| Q1 2020 | $7,395,000 | +1558.1% | 82,280 | +629.0% | 0.01% | +600.0% |
| Q3 2019 | $446,000 | +34.7% | 11,286 | +40.2% | 0.00% | 0.0% |
| Q2 2019 | $331,000 | +32.4% | 8,048 | +25.7% | 0.00% | 0.0% |
| Q1 2018 | $250,000 | -43.9% | 6,404 | -39.1% | 0.00% | 0.0% |
| Q4 2017 | $446,000 | -69.5% | 10,519 | -73.1% | 0.00% | -80.0% |
| Q3 2017 | $1,461,000 | +558.1% | 39,137 | +758.8% | 0.01% | +400.0% |
| Q4 2015 | $222,000 | -55.3% | 4,557 | -68.8% | 0.00% | -83.3% |
| Q2 2014 | $497,000 | – | 14,621 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Artal Group S.A. | 1,400,000 | $133,378,000 | 3.73% |
| Foresite Capital Management III, LLC | 42,030 | $4,004,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 257,249 | $24,508,000 | 2.23% |
| Cormorant Asset Management, LP | 600,000 | $57,162,000 | 2.18% |
| Avoro Capital Advisors LLC | 1,040,000 | $99,081,000 | 1.96% |
| QVT Financial LP | 101,396 | $9,660,000 | 1.64% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,100,000 | $200,067,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 155,000 | $14,767,000 | 1.60% |
| Parkman Healthcare Partners LLC | 57,500 | $5,478,000 | 1.54% |
| Ikarian Capital, LLC | 187,700 | $17,882,000 | 1.42% |